CSL Limited’s
(ASX:CSL) net profit has risen 4.5 per cent to $983 million in fiscal 2012. The drug maker says its profit result was impacted by a foreign currency exchange charge of more than $100 million resulting from the strong Australian dollar.
CEO Dr Brian McNamee says the board will consider new capital management initiatives including a further on-market share buyback program of up to $900 million.
The company’s chief expects trading conditions to remain similar next year, with CSL anticipating a 12 per cent rise in profit in fiscal 2013.
CSL has declared a final dividend of 47 cents, bringing its final payout to 83 cents unfranked.
